Axsome Therapeutics (AXSM) Depreciation and Depletion (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Depreciation and Depletion data on file, last reported at $116000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation and Depletion fell 22.15% year-over-year to $116000.0; the trailing twelve-month figure through Mar 2026 stood at $470000.0 (down 14.39% YoY), and the FY2025 full-year result was $503000.0, down 5.45% from the prior year.
• Depreciation and Depletion improved to $116000.0 in Q1 2026, from $114000.0 in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $149000.0 in Q1 2025 to a low of $37000.0 in Q1 2022.
• A 5-year average of $110176.5 and a median of $120000.0 in 2025 frame the typical range for Depreciation and Depletion.
• Across the five-year window, Depreciation and Depletion soared 587.25% in 2022 and declined 22.15% in 2026, its largest moves.
• Tracing AXSM's Depreciation and Depletion over 5 years: stood at $85000.0 in 2022, then surged by 56.47% to $133000.0 in 2023, then dropped by 3.01% to $129000.0 in 2024, then slipped by 11.63% to $114000.0 in 2025, then increased by 1.75% to $116000.0 in 2026.
• Business Quant data shows AXSM's Depreciation and Depletion at $116000.0 in Q1 2026, $114000.0 in Q4 2025, and $120000.0 in Q3 2025.